Login to Your Account



Earnings Roundup

Arena Yanks MAA, Falls on Belviq Launch Delay in U.S.

By Jennifer Boggs
Managing Editor

Monday, May 6, 2013

Shares of Arena Pharmaceuticals Inc. were down nearly 10 percent Friday following Thursday's after-market release of first-quarter earnings, which included news that the San Diego-based biotech is pulling its European marketing application for obesity drug Belviq (lorcaserin), though the bigger disappointment may be the ongoing delay in Belviq's U.S. launch.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription